Ketolide Anti-infective Compounds Resolving Gastrointestinal Trade-offs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics, such as erythromycin, face challenges in maintaining antibacterial efficacy while minimizing gastrointestinal motility effects and preventing antibiotic resistance, particularly in treating microbial infections caused by resistant bacteria.
Innovation Solution
Development of ketolide anti-infective compounds with specific structural modifications, including compounds represented by formula I, which inhibit microbial pathogen proliferation and treat infections by administering a therapeutically effective amount, thereby reducing antibacterial activity in the gastrointestinal tract and addressing resistance issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If erythromycin and its derivatives are used to treat microbial infections, then antibacterial activity is achieved, but gastrointestinal motility effects and antibiotic resistance occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of erythromycin through systematic variations in substituents R1-R6, ring sizes (m=0 or 1), and functional groups (X=O, NH, or CH). These structural parameter changes produce ketolide compounds with improved antibacterial activity against resistant strains while reducing gastrointestinal motility effects, as demonstrated by the selective activity profile against various bacterial pathogens.
2Reliability
If semi-synthetic erythromycin antibiotics like clarithromycin and telithromycin are developed, then acid stability and activity against resistant bacteria are improved, but structural complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions (R1-R6) of the erythromycin scaffold. For example, the 3-keto group in telithromycin and various substituent patterns in formula I compounds provide localized modifications that enhance acid stability and antibacterial activity against resistant strains while maintaining the core macrolide structure.
Solution Approach 2:
The patent employs composite materials by combining the erythromycin core structure with diverse substituent groups (aryl, heterocyclo, alkyl, alkenyl, alkynyl) and functional moieties (carbamate, keto, hydroxyl groups). This composite approach creates ketolide compounds with tailored properties that achieve both acid stability and enhanced activity against resistant bacteria.
3Ease of operation
If motilide derivatives are designed for gastrointestinal motility disorders, then gastrointestinal motility is stimulated, but antibacterial activity must be eliminated to prevent resistance
Solution Approach 1:
The patent applies dynamics by creating a flexible substituent framework in formula I where R1-R6 can be independently varied to tune the compound's properties. This dynamic structural flexibility allows optimization for either antibacterial activity (when specific substituents are present) or motility stimulation (when antibacterial groups are modified or removed), enabling the same core structure to serve different therapeutic purposes.
Data Source
AI summary
Compounds according to formula Iwherein m is 0 or 1;X isand R1, R2, R3 R4, and R5 are as defined herein, are useful as anti-infective agents.